Dexmedetomidine Nasal Spray for the Treatment of Panic Attacks in Adults
Status:
NOT_YET_RECRUITING
Trial end date:
2028-08-30
Target enrollment:
Participant gender:
Summary
Panic attacks affect 13.2% of adults globally, with acute treatments (e.g., benzodiazepines) carrying dependency risks. Dexmedetomidine, an -adrenergic agonist, achieves peak plasma levels in 5-15 min via nasal delivery and may offer rapid, non-invasive relief for acute panic attacks. Despite preclinical evidence of anxiolytic effects, no randomized trials have evaluated its efficacy for panic attacks.